Literature DB >> 25680601

Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy.

D Michael Lovelock1, Alessandra P Messineo2, Brett W Cox3, Marisa A Kollmeier2, Michael J Zelefsky2.   

Abstract

PURPOSE: To compare the potential benefits of continuous monitoring of prostate position and intervention (CMI) using 2-mm displacement thresholds during stereotactic body radiation therapy (SBRT) treatment to those of a conventional image-guided procedure involving single localization prior to treatment. METHODS AND MATERIALS: Eighty-nine patients accrued to a prostate SBRT dose escalation protocol were implanted with radiofrequency transponder beacons. The planning target volume (PTV) margin was 5 mm in all directions, except for 3 mm in the posterior direction. The prostate was kept within 2 mm of its planned position by the therapists halting dose delivery and, if necessary, correcting the couch position. We computed the number, type, and time required for interventions and where the prostate would have been during dose delivery had there been, instead, a single image-guided setup procedure prior to each treatment. Distributions of prostate displacements were computed as a function of time.
RESULTS: After the initial setup, 1.7 interventions per fraction were required, with a concomitant increase in time for dose delivery of approximately 65 seconds. Small systematic drifts in prostate position in the posterior and inferior directions were observed in the study patients. Without CMI, intrafractional motion would have resulted in approximately 10% of patients having a delivered dose that did not meet our clinical coverage requirement, that is, a PTV D95 of >90%. The posterior PTV margin required for 95% of the dose to be delivered with the target positioned within the PTV was computed as a function of time. The margin necessary was found to increase by 2 mm every 5 minutes, starting from the time of the imaging procedure.
CONCLUSIONS: CMI using a tight 2-mm displacement threshold was not only feasible but was found to deliver superior PTV coverage compared with the conventional image-guided procedure in the SBRT setting.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25680601     DOI: 10.1016/j.ijrobp.2014.10.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Robustness Analysis for External Beam Radiation Therapy Treatment Plans: Describing Uncertainty Scenarios and Reporting Their Dosimetric Consequences.

Authors:  Adam D Yock; Radhe Mohan; Stella Flampouri; Walter Bosch; Paige A Taylor; David Gladstone; Siyong Kim; Jason Sohn; Robert Wallace; Ying Xiao; Jeff Buchsbaum
Journal:  Pract Radiat Oncol       Date:  2018-12-15

2.  Impact of robotic ultrasound image guidance on plan quality in SBRT of the prostate.

Authors:  Stefan Gerlach; Ivo Kuhlemann; Floris Ernst; Christoph Fürweger; Alexander Schlaefer
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

3.  Robotic ultrasound-guided SBRT of the prostate: feasibility with respect to plan quality.

Authors:  Stefan Gerlach; Ivo Kuhlemann; Philipp Jauer; Ralf Bruder; Floris Ernst; Christoph Fürweger; Alexander Schlaefer
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-07-12       Impact factor: 2.924

Review 4.  Integrated MRI-guided radiotherapy - opportunities and challenges.

Authors:  Paul J Keall; Caterina Brighi; Carri Glide-Hurst; Gary Liney; Paul Z Y Liu; Suzanne Lydiard; Chiara Paganelli; Trang Pham; Shanshan Shan; Alison C Tree; Uulke A van der Heide; David E J Waddington; Brendan Whelan
Journal:  Nat Rev Clin Oncol       Date:  2022-04-19       Impact factor: 65.011

5.  Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Authors:  Michael Wahl; Martina Descovich; Erin Shugard; Dilini Pinnaduwage; Atchar Sudhyadhom; Albert Chang; Mack Roach; Alexander Gottschalk; Josephine Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-08

6.  Target migration from re-inflation of adjacent atelectasis during lung stereotactic body radiotherapy.

Authors:  Bijing Mao; Vivek Verma; Dandan Zheng; Xiaofeng Zhu; Nathan R Bennion; Abhijeet R Bhirud; Maria A Poole; Weining Zhen
Journal:  World J Clin Oncol       Date:  2017-06-10

7.  Adaptive Imaging Versus Periodic Surveillance for Intrafraction Motion Management During Prostate Cancer Radiotherapy.

Authors:  Xiangyu Ma; Huagang Yan; Ravinder Nath; Zhe Chen; Haiyun Li; Wu Liu
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

8.  Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.

Authors:  Rosario Mazzola; Gianluisa Sicignano; Francesco Cuccia; Claudio Vitale; Michele Rigo; Niccolò Giaj-Levra; Luca Nicosia; Vanessa Figlia; Francesco Ricchetti; Giorgio Attinà; Edoardo Pastorello; Antonio De Simone; Davide Gurrera; Stefania Naccarato; Ruggero Ruggieri; Filippo Alongi
Journal:  Br J Radiol       Date:  2021-07-20       Impact factor: 3.629

9.  Feasibility study of ultrasound imaging for stereotactic body radiation therapy with active breathing coordinator in pancreatic cancer.

Authors:  Lin Su; Iulian Iordachita; Yin Zhang; Junghoon Lee; Sook Kien Ng; Juan Jackson; Ted Hooker; John Wong; Joseph M Herman; H Tutkun Sen; Peter Kazanzides; Muyinatu A Lediju Bell; Chen Yang; Kai Ding
Journal:  J Appl Clin Med Phys       Date:  2017-06-02       Impact factor: 2.102

10.  Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking.

Authors:  Avinash R Chaurasia; Kelly J Sun; Christopher Premo; Timothy Brand; Brent Tinnel; Stacie Barczak; John Halligan; Michael Brown; Dusten Macdonald
Journal:  Adv Radiat Oncol       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.